Group Challenges Proposed Limits on Vial Labeling - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Group Challenges Proposed Limits on Vial Labeling

ePT--the Electronic Newsletter of Pharmaceutical Technology

In late May 2010, the Consortium for the Advancement of Patient Safety (CAPS) told a meeting of the US Pharmacopeia’s (USP’s) Nomenclature Expert Committee that the latter’s proposal to restrict printing on ferrules and cap overseals was ambiguous and could unintentionally reduce patient safety. CAPS’s comments were based on a three-part study that the group commissioned to evaluate USP’s proposed revision of USP General Chapter <1>, “Injections, Labeling on Ferrules and Cap Overseals,” which is scheduled to become effective in May 2011.
USP had held that healthcare professionals should rely exclusively on package inserts and vial labels for information about drug products. The organization proposed limiting cap messages to a small set of drugs that pose a risk of imminent harm or death in the event of medication errors. In 2009, a representative of the US Food and Drug Administration recommended that a human-factors engineering study be conducted to provide data to evaluate USP’s proposal.
CAPS hired Anthony Andre, founding principal of Interface Analysis Associates and adjunct professor of human factors and ergonomics at San Jose State University, to study the relationship between patient safety and messages on ferrule and cap overseals. The resulting three-phase study includes a literature review; an online survey of healthcare practitioners, which was conducted in December 2009; and a human-factors research study, in which healthcare practitioners participated in March 2010.
Andre’s literature review did not find any reported incidents of medication errors that were associated with cap messages. In addition, the human-factors principles found in scientific literature did not support the premises of USP’s proposal.
The majority of respondents to the online survey of healthcare practitioners said that the USP proposal would prohibit important cap messages. About 80% of respondents predicted that medication errors would increase if many of the currently allowed cap messages were prohibited. Roughly 69% of respondents disagreed with USP’s approach to making warnings more prominent for healthcare professionals.
Participants in the empirical human-factors study had to select the correct drug from a group of drug vials, some of which had cap labels that would be prohibited by the USP proposal, and some of which did not. Participants selected drugs with cap labels more accurately and more quickly than they selected unlabeled drugs, according to the report. Participants rated the labeled drugs as easy to use more often than the unlabeled drugs. The 20 participants included nurses, physicians, and pharmacists who normally handle drug vials and check drugs against prescriptions.
“The science of human factors, coupled with our recent research, shows that the cap area is an underutilized and highly visible area of the drug vial that is well-suited to present key medication and warning information toward aiding healthcare practitioners in selecting the correct drug in the correct concentration and dose,” said Andre in a CAPS press release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here